|1.79||-0.1800||-9.14%||Vol 370.29K||1Y Perf -76.82%|
|Sep 22nd, 2023 16:00 DELAYED|
|- -||0.02 1.12%|
|Target Price||23.83||Analyst Rating||Strong Buy 1.00|
|Potential %||1.23K||Finscreener Ranking||— -|
|Insiders Trans % 3/6/12 mo.||100/100/-81||Value Ranking||★★★+ 52.46|
|Insiders Value % 3/6/12 mo.||100/100/-97||Growth Ranking||★★★ 50.64|
|Insiders Shares Cnt. % 3/6/12 mo.||100/100/-71||Income Ranking||— -|
|Price Range Ratio 52W %||-1.43||Earnings Rating||—|
|Market Cap||85.57M||Earnings Date||3rd Nov 2023|
Today's Price Range
|Moving Averages:||Strong Sell|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||3rd Nov 2023|
|Estimated EPS Next Report||-0.77|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||265.24K|
|Avg. Monthly Volume||201.69K|
|Avg. Quarterly Volume||312.86K|
BioAtla Inc. (NASDAQ: BCAB) stock closed at 1.79 per share at the end of the most recent trading day (a -9.14% change compared to the prior day closing price) with a volume of 370.29K shares and market capitalization of 85.57M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 36 people. BioAtla Inc. CEO is Jay M. Short.
The one-year performance of BioAtla Inc. stock is -76.82%, while year-to-date (YTD) performance is -78.3%. BCAB stock has a five-year performance of %. Its 52-week range is between 1.93 and 11.73, which gives BCAB stock a 52-week price range ratio of -1.43%
BioAtla Inc. currently has a PE ratio of -3.00, a price-to-book (PB) ratio of 2.17, a price-to-sale (PS) ratio of 439.68, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -43.85%, a ROC of -53.94% and a ROE of -54.83%. The company’s profit margin is -%, its EBITDA margin is -39 848.00%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from BioAtla Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.77 for the next earnings report. BioAtla Inc.’s next earnings report date is 03rd Nov 2023.
The consensus rating of Wall Street analysts for BioAtla Inc. is Strong Buy (1), with a target price of $23.83, which is +1 231.28% compared to the current price. The earnings rating for BioAtla Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
BioAtla Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
BioAtla Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 41.70, ATR14 : 0.15, CCI20 : -128.14, Chaikin Money Flow : -0.32, MACD : -0.20, Money Flow Index : 12.85, ROC : -31.42, RSI : 26.35, STOCH (14,3) : 1.10, STOCH RSI : 0.00, UO : 26.74, Williams %R : -98.90), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of BioAtla Inc. in the last 12-months were: Christian Vasquez (Buy at a value of $47 970), Jay M. Short (Buy at a value of $100 862), Jay Short (Buy at a value of $100 776), Sylvia McBrinn (Buy at a value of $52 433), Vasquez Christian (Buy at a value of $48 000)
Wed, 02 Aug 2023 04:30 GMT Analysts Offer Insights on Healthcare Companies: BioAtla (BCAB), Exelixis (EXEL) and Steris (STE)- TipRanks. All rights reserved.
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
This could take some time, please wait.